Tag Archives: Earnings

Wednesday, August 14th 2019 at 9:16pm UTC Moves into new San Francisco Bay Area R&D facility, comprising approximately 15,700-square-feet of office and lab space, including cGMP-capable manufacturing suite. Strengthens leadership at Board level by appointment of regenerative medicine leader Dr. Michael H. May, CEO of Canada’s Centre for Commercialization of …

Thursday, August 15th 2019 at 11:00am UTC – Quarter marked by reinvigorated focus on purposefully built strategic business units leveraging science-driven cannabinoid research to address areas of significant unmet needs and access growing markets – – Robust business development initiative to build biopharmaceuticals pipeline underway with expectation to announce at …

Wednesday, August 14th 2019 at 12:00pm UTC BEDFORD, Mass.–(BUSINESS WIRE)– Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2019. “We are making efficient and …

Thursday, August 15th 2019 at 8:05pm UTC BEIJING–(BUSINESS WIRE)– Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the second quarter ended June 30, 2019. Second Quarter and First Half of 2019 Financial Summary Sales …

Wednesday, August 14th 2019 at 8:20pm UTC VIENNA, Va.–(BUSINESS WIRE)– CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended June 30, 2019. The Company also reported key clinical and corporate developments achieved during the quarter. Clinical and Corporate Developments included: CEL-SCI’s Phase 3 head and neck …

Tuesday, August 13th 2019 at 11:30am UTC ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study ALPN-202 Submission for Clinical Trial Authorization Anticipated by Year End 2019 SEATTLE–(BUSINESS WIRE)– Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other …

Tuesday, August 13th 2019 at 12:00pm UTC — Net sales increase 13% to $8,071,000, operating income was $49,000 — KAILUA KONA, Hawaii–(BUSINESS WIRE)– Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announced financial results for the first quarter of fiscal year 2020, …

Tuesday, August 13th 2019 at 8:05pm UTC IRVINE, Calif.–(BUSINESS WIRE)– Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended June 30, 2019. Operational Highlights Announced results from …

Tuesday, August 13th 2019 at 8:02pm UTC MENLO PARK, Calif.–(BUSINESS WIRE)– Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today reported financial results for the second quarter ended June 30, 2019. Second Quarter 2019 Highlights Record revenues of $15.8 million in the second quarter of 2019, versus …

Tuesday, August 13th 2019 at 8:05pm UTC IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal quarter ended June 30, 2019. Recent Business Highlights Announced the …